Casma Therapeutics
Harnessing the power of autophagy to bring cures to patients with serious diseases.
Harnessing the power of autophagy to bring cures to patients with serious diseases.
Casma Therapeutics is a biotechnology company founded in 2017 and based in the United States. The company's slogan, "Harnessing the power of autophagy to bring cures to patients with serious diseases," reflects its focus on utilizing the natural cellular process of autophagy to develop advanced therapeutics. With a mission to design powerful new medicines for a broad range of diseases, Casma Therapeutics has garnered significant attention from investors.
In its latest funding round, Casma Therapeutics successfully raised $46.00M in a Series C investment on 15 November 2022. Notably, the round attracted a diverse group of investors, including Amgen Ventures, Mirae Asset, The Column Group, Third Rock Ventures, Astellas Venture Management, Eisai, Euclidean Capital, Ono Venture Investment, Schroders Capital, and Eventide Management Partners.
With this substantial investment, Casma Therapeutics is well-positioned to advance its innovative approach to drug development and potentially revolutionize the treatment of serious diseases. The company's emphasis on leveraging autophagy sets it apart in the biotechnology and healthcare industries, offering promising potential for addressing unmet medical needs and delivering impactful cures to patients.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $46.00M | 10 |
|
15 Nov 2022 |
| Series B | $50.00M | - | 10 Sep 2020 | |
| Grant | $370.00K | - | 29 May 2019 | |
| Series A | $58.50M | - | 03 May 2018 |
No recent news or press coverage available for Casma Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
